1.4M
Downloads
1115
Episodes
Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com
Episodes
Saturday Nov 19, 2022
Saturday Nov 19, 2022
Treatment Considerations in Axial Spondyloarthritis
What Happens after you stop biologics?
What lifestyle factors affect TNF inhibitor efficacy in AxSpA?
Which is better for AxSpA? IL-17i or TNFi?
Women vs. Men: Response to Treatment in Seronegative Arthritis
Saturday Nov 19, 2022
Saturday Nov 19, 2022
Opioids and Health Care Utilization in PsA and AS
Reproductive health in a post-Roe world
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Sunday (Day 2): ACR 22 Daily Recap
Tapering TNFi in nonradiographic AxSpA
The CONSUL Trial: Ankylosing Spondylitis
Saturday Nov 19, 2022
Saturday Nov 19, 2022
Comorbidities in Ankylosing Spondylitis
Early Diagnosis of Axial Spondyloarthritis
Fertility issues in SpA
Gender in AxSpa
Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLE
JAK inhibitors in rheumatic diseases
Opioid use in PsA and SpA
Saturday Nov 19, 2022
Saturday Nov 19, 2022
ACR22 Daily Recap: Saturday Recap
AI Future of Sacroiliitis Assessment
Artificial Intelligence in Detecting Sacroiliitis
Axial Spondyloarthritis: gender differences
Can we alter neonatal gut microbiome to prevent spondyloarthritis?
Comorbidities in Axial Spondyloarthritis
Do Disease Activity Measures Really Capture AS in Women?
Friday Nov 18, 2022
Friday Nov 18, 2022
Dr. Jack Cush and Dr. Arthur Kavanaugh discuss, dissect and deliberate the sessions and data presented at the ACR22 meeting in Philadelphia.
Friday Nov 18, 2022
Thursday Nov 17, 2022
Thursday Nov 17, 2022
Wednesday - SpA
Panelists: Drs. Lianne Gensler, Antoni Chan, Akhil Sood, Eric Dein, Sheila Reyes, Catherine Sims
Wednesday Nov 16, 2022
Wednesday Nov 16, 2022
Get the Skinny on Bimekizumab in PsA
Dr. Janet Pope discusses abstract presented at ACR22 Convergence in Philadelphia, PA.
L02: Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Low dose steroids can negatively impact bone healthDr. Janet Pope discusses abstract L01 presented at ACR22 Convergence in Philadelphia, PA.
L01: Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study
The First Head to Head trial in Axial Spondyloarthritis
Dr. Lianne Gensler discusses abstract L15 presented at ACR22 Convergence in Philadelphia, PA.
L15: Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study
Why Clinical Trials?
Dr. Guillermo Valenzuela talks about the importance of clinical trials from ACR22 Convergence in Philadelphia, PA.
Wednesday Nov 16, 2022
Wednesday Nov 16, 2022
RheumNow faculty to recap the best and most interesting data presented at ACR2022 in the area of PsA.
Tuesday - PsA (7pm ET)
Panelists: Drs. Rachel Tate, Robert Chao, Olga Petryna, Elaine Husni, Patricia Harkins
Wednesday Nov 16, 2022
Wednesday Nov 16, 2022
RheumNow faculty recap the best and most interesting data presented at ACR22 in RA.
Panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, Julian Segan